About Eisai US
At Eisai Inc., the objective is human health care (hhc). Our primary focus is on patients and their families, striving to enhance the advantages that health care offers. As the U.S. pharmaceutical arm of Eisai Co., Ltd., headquartered in Tokyo, we are deeply committed to patient care, which motivates our work in discovering and developing innovative treatments aimed at addressing unmet medical needs. Eisai operates as a fully integrated pharmaceutical company with two global business divisions: oncology and neurology (covering dementia-related and neurodegenerative diseases). Each division functions as a comprehensive global operation, encompassing discovery, development, and marketing. Our U.S. headquarters, along with commercial and clinical development operations, are based in New Jersey; discovery laboratories are located in Massachusetts and Pennsylvania; and our global demand chain organization is situated in Maryland and North Carolina. For further details about Eisai Inc., please visit www.eisai.com/US. User-generated comments and posts on this site are not produced or managed by Eisai Inc., and Eisai bears no responsibility for such content.
Executive Leadership Team
Organizational Chart — Preview
Eisai US Executive Leadership Team
Business Focus Areas
Eisai US Org Chart & Organizational Structure
Eisai US, the American arm of the global pharmaceutical company Eisai Co., Ltd., operates with a clearly defined organizational structure. The organization is led by Tatsuyuki Yasuno, who serves as Senior Vice President of Eisai Co., Ltd., President of the Americas Region, and Chairman and Chief Executive Officer of Eisai Inc. Reporting to him is Cynthia Schwalm, who holds the role of President. Under the leadership of Tatsuyuki Yasuno, the company is organized into several key functions: Finance, Information Technology, Strategy, Supply Chain, and Compliance. The Finance function is headed by Brian Harraka, CPA, CGMA, who holds the position of Group Chief Financial Officer. Reporting to him is Keisuke Muramatsu, the Executive Director of Finance and Commercialization Alliance for Alzheimer's Disease. In the Information Technology division, Makoto Hoketsu serves as the Chief Information Officer. The division further branches into Enterprise Architecture and Digital Transformation and Innovation. Jennifer N. is the Executive Director of Global Enterprise Architecture, Risk, and Compliance, and Vijay Venugopal Iyengar, MS, MBA, MPH, is the Executive Director of Global Digital Business Transformation covering Sales, Marketing, and Enterprise Strategy. The Strategy function is led by Susan Mayer, Executive Director of Regulatory Strategy for Oncology, and Adelle Berezinsky, Pharm.D., Executive Director of Global and US Medical Communications and Digital Strategy. Within Strategy, the Corporate Strategy sub-function is managed by Bryan Harfenist, who holds the title of Executive Director of Corporate Strategy. The Supply Chain function includes a Procurement sub-function. Brian Harraka, CPA, CGMA, also serves as the head of Procurement, and Terrell Carothers, Ph.D., MBB, SSM, is the Executive Director of Strategic Procurement and Site Services. Lastly, the Compliance function is overseen by Nina Kutner, the Executive Director of Corporate Ethics and Compliance. This organizational structure reflects the company's commitment to a multidisciplinary approach across finance, technology, strategy, operations, and compliance.